Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06228963
PHASE2

Orelabrutinib in the Treatment of HP-positive Gastric MALT Lymphoma

Sponsor: Fudan University

View on ClinicalTrials.gov

Summary

Describe the efficacy and safety of Orelabrutinib in the treatment of HP-positive gastric MALT lymphoma

Official title: Orelabrutinib in the First-line Treatment of HP-positive Gastric MALT Lymphoma: a Multicenter, Open-label, Randomized Controlled Trial

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

160

Start Date

2024-03

Completion Date

2028-01

Last Updated

2024-02-23

Healthy Volunteers

No

Interventions

DRUG

Triple therapy for eradication of Helicobacter Pylori and Orelabrutinib

Triple therapy for H. pylori (oral administration for 2 weeks, followed by a 1-week break) plus Orelabrutinib for 8 weeks (or until progression, intolerable toxicity, death, or withdrawal from the study)

DRUG

Triple therapy for eradication of Helicobacter Pylori

Triple therapy for H. pylori (oral administration for 2 weeks, followed by a 1-week break)

Locations (1)

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China